MARKET

ARAV

ARAV

Aravive Inc
NASDAQ
1.580
+0.110
+7.48%
After Hours: 1.630 +0.05 +3.16% 19:18 05/26 EDT
OPEN
1.560
PREV CLOSE
1.470
HIGH
1.610
LOW
1.420
VOLUME
287.07K
TURNOVER
0
52 WEEK HIGH
2.460
52 WEEK LOW
0.5801
MARKET CAP
94.55M
P/E (TTM)
-0.7056
1D
5D
1M
3M
1Y
5Y
EF Hutton Reiterates Aravive (ARAV) Buy Recommendation
NASDAQ · 18h ago
HC Wainwright & Co. Reiterates Aravive (ARAV) Buy Recommendation
NASDAQ · 18h ago
EF Hutton Reiterates Buy on Aravive, Maintains $10 Price Target
Benzinga · 1d ago
HC Wainwright & Co. Reiterates Buy on Aravive, Maintains $12 Price Target
Benzinga · 1d ago
BRIEF-Aravive To Present Promising Updated Data From Phase 2 Trial Of Batiraxcept In Combination With Cabozantinib In Clear Cell Renal Cell Carcinoma At ASCO 2023
Reuters · 2d ago
Aravive Inc: Current report
Press release · 2d ago
Analyst Expectations for Aravive's Future
Benzinga · 2d ago
Analysts Offer Insights on Healthcare Companies: Sonnet BioTherapeutics Holdings (SONN), Aravive (ARAV) and Cyclacel Pharmaceuticals (CYCC)
TipRanks · 2d ago
More
About ARAV
Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).

Webull offers kinds of Aravive Inc stock information, including NASDAQ:ARAV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARAV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARAV stock methods without spending real money on the virtual paper trading platform.